Introduction
Taxol (paclitaxel) is a highly active anticancer drug against a number of tumours including breast, ovarian, lung, bladder, oesophageal and head and neck carcinomas (Rowinsky, 1997) . Recently, it has been used in the treatment of androgen-independent prostate cancer with promising results (Urakami et al., 2002) . Taxol binds to and stabilizes microtubules preventing deploymerization, which results in excessively stable mitotic spindles and disturbance of chromosome segregation at metaphase (Horwitz, 1992) . It has been generally believed that the antitumour effect of taxol is mainly due to its interference with the normal function of microtubule and the consequence arrest of the cell cycle at mitosis (Jordan et al., 1993) . However, recently, a number of reports have shown that taxol-induced cell death is via multiple signalling pathways that are independent of microtubule stabilization or mitotic arrest (Moos and Fitzpatrick, 1998; Huang et al., 2000; McDaid and Horwitz, 2001) . For example, taxol-induced apoptosis in breast cancer cells requires downregulation of IkB-a, which in turn activates NF-kB leading to apoptosis (Huang et al., 2000) . Activation of MAPK pathways by taxol in HeLa cells also leads to a time-dependent increase of poly(ADP-ribose) polymerase (PARP) cleavage and apoptosis (McDaid and Horwitz, 2001 ). In addition, taxol-induced apoptosis has also been associated with phosphorylation of Bcl-2, which is thought to inhibit its ability to interfere with proapoptotic proteins, such as Bax, leading to apoptosis (Haldar et al., 1996; Huang et al., 1999) . Furthermore, a study on differential gene expression in mouse cells treated with taxol identified a number of genes encoding transcriptional regulators and factors that modulate apoptosis, rather than genes associated with microtubule stabilization (Moos and Fitzpatrick, 1998) . These results indicate that in addition to interfering with microtubules, taxol may induce cytotoxicity through multiple pathways related to apoptosis.
Although taxol is one of the most effective anticancer drugs, acquired resistance often develops in cancer cells after a number of exposures. This type of resistance is a frequent clinical problem, which limits the effectiveness of chemotherapy. Therefore, it is equally important to understand the mechanisms involved in the development of taxol resistance in order to improve treatment efficiency of human cancer. In addition to the welldocumented overexpression of P-glycoprotein in taxol resistance (Germann, 1996; Dumontet and Sikic, 1999) , alterations in the tubulin gene are also frequently reported (Giannakakou et al., 1997; Kavallaris et al., 1997; Ranganathan et al., 1998) . However, evidence so far cannot fully explain the mechanisms responsible for acquired taxol resistance in human cancer. In the present study, we report a novel function of TWIST, a basic helix-loop-helix protein, and its role in the development of acquired taxol resistance in human nasopharyngeal carcinoma cells (HNE1). The taxolresistant subline HNE1-T3 cells showed upregulation of TWIST at both mRNA and proteins levels and were also crossresistant to vincristine, another microtubuletargeting anticancer drug with a different mechanism, but not to DNA-damaging agents, anthracyclines or antimetabolites. In addition, increased TWIST expression was correlated with taxol resistance in three additional cancer types including bladder, ovarian and prostate cancers. Ectopic expression of the TWIST gene not only resulted in resistance to both taxol and vincristine in the original parental line HNE1 cells, but also in an additional NPC cell line (TW04) and bladder cancer cells. Our evidence suggests a novel factor that plays a central role in the development of resistance to microtubule-disrupting chemotherapeutic drugs in human cancer.
Materials and methods

Cell lines and culture conditions
Nine human cancer cell lines derived from nasopharyngeal (HNE1 (Glaser et al., 1989) , CNE2 (Gu et al., 1983) , TW04 (Lin et al., 1990) ), bladder (RT112, MGHU1 (obtained from America Tissue Culture Collection, ATCC)), ovarian (Ovca433, Ovca432 (Rauh-Adelmann et al., 2000; Wang et al., 2002) ) and prostate (PC3, LNCaP (obtained from ATCC)) carcinomas were maintained in RPMI 1640 (Life Technologies, Inc.) supplemented with 2 mM L-glutamine and 5% (v/v) fetal calf serum at 371C. The cultures were grown for a maximum of 10 passages before retrieving fresh cells from the frozen stock. The HNE1-T3 cell line was generated by exposure to increasing concentrations of taxol (starting at 0.2 to 2 ng/ml) for approximately 12 months and then cultured in drug-free RPMI 1640 as described above for maintenance.
Colony-forming assay
A total of 500 cells were plated in six-well plates, resulting in 100-150 colonies per well after approximately 2 weeks culture. Taxol (Calbiochem, La Jolla, CA, USA), vincristine, cisplatin, carboplatin, 5-fluorouracil (5-FU) (David Bull Laboratories, Victoria, Australia), epirubicin (Pharmacia and Upjohn, USA), cyclophosphamid (ASTA Medica, Frankfurt, Germany) or doxorubicin (EBEWE, Unterach, Austria) was added 24 h after plating, and colonies that consisted of more than 50 cells were scored and compared with the solventtreated controls. Two wells were used for each drug concentration and each experiment was repeated at least three times. The cell survival curves showed the means and standard deviations of at least three independent experiments.
Comparative genome hybridization analysis
Detailed experimental procedures have been described previously (Guan et al., 2000) . Briefly, metaphase cells were prepared according to standard procedures from peripheral blood lymphocytes from a healthy male donor. DNA (1 mg) from HNE1 or HNE1-T3 cells and normal reference DNA was labelled with Spectrum Green-dUTP and Spectrum Red-dUTP (Vysis, Downers Grove, IL, USA), respectively, by nick translation. The reaction was performed for 4 h at 151C, and labelled probes were then purified by precipitation. A measure of 300 ng of each labelled probe was used for hybridization and the repetitive genomic sequences within the probe were blocked with 10 mg of human Cot-1 DNA. The slide containing normal metaphase cells was then treated with RNase (100 mg/ ml) at 371C for 1 h, and then denatured at 751C in 70% formamide, 2 Â SSC for 5 min. Hybridization mix (50% formamide, 2 Â SSC, 10% dextran sulphate) containing probes and human Cot-1 DNA was denatured at 751C for 5 min, incubated at 371C for 30 min, and then hybridized to the denatured metaphase chromosomes at 371C in a moist chamber for 2 days. After hybridization, the slide was washed in 4 Â SSC, 0.3% Tween 20 at 851C for 2 min, dehydrated through an ethanol series (70, 85, 100%), and then air-dried. After washing, the slide was counterstained with 1 mg/ml of DAPI in an antifade solution. The hybridized metaphase chromosomes were analysed using a digital image analysis system containing a Zeiss Axioplan 2 microscope equipped with a Sensys cooled-charged device camera (Photometrics Ltd, Tucson, AZ, USA). Five images of each metaphase cell were captured using filter wheel-mounted, single-band excitation rhodamine, FITC and DAPI filters. Image analysis was carried out using the Quips CGH program (Vysis, Downers Grove, IL, USA). A total of 10 metaphase cells were analysed to generate fluorescence ratio profiles in each case.
RT-PCR analysis of TWIST gene expression
Total RNA was isolated from HNE1 and HNE1-T3 cells using Trizol reagent with procedure according to the manufacturer's protocol (Life Technologies, Gaithersburg, MD, USA). For reverse transcriptase (RT)-PCR, cDNA was synthesized by the Superscript TM First Strand Synthesis System (Life Technologies, Gaithersburg, MD, USA). The cDNA was then amplified by PCR with TWIST-specific primers (sense: 5 0 -CTGAGCAACAGCGAGGAAGA-3 0 ; antisense: 5 0 -CTGGTAGAGGAAGTCGATGT-3 0 ). The PCR conditions were as follows: 34 cycles at 941C for 1 min, 501C for 1 min and 721C for 1 min, and a final extension at 721C for 5 min. Preliminary experiments were conducted to ensure that the PCR conditions were at the logarithmic phase of the PCR reaction. The cDNA of b-actin was amplified as a control for the amount of cDNA present in each sample (primer details: sense: 5 0 -GTC GGG CGC CCC AGG CAC CA-3 0 , antisense: 5 0 -CTC CTT AAT GTC ACG CAC GAT TTC-3 0 ) (Ling et al., 2001) . PCR products were electrophoresed on 2% agarose gels and were analysed using a gel documentation system (UltraViolet Product Limited, CA, USA). The relative expression levels were generated by comparing the density to the controls and indicated underneath each gel.
Western blotting analysis
Experiments were carried out as previously described (Ling et al., 2002) . Briefly, cell lysates were prepared by suspending Role of TWIST in anticancer drug resistance X Wang et al cell pellets in lysis buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS) including proteinase inhibitors (1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mM PMSF). Protein concentration was measured using the D C Protein Assay kit (Bio-Rad, Hercules, CA, USA). Equal amounts of protein (30 mg) were loaded onto an SDSpolyacrylamide gel for electrophoresis and then transferred on a PVDF membrane (Amersham, Piscataway, NJ, USA). The membrane was then incubated with primary antibodies for 1 h at room temperature against TWIST, MDR-1, MAD2, p55CDC, p53, p21 Waf1 , MDM2, Bcl-2 and Bax (Santa Cruz Biotechnology, CA, USA), and tubulin (Neomarkers, Union city, CA, USA). After washing with TBS-T, the membrane was incubated with secondary antibodies against rabbit IgG and the signals were visualized by ECL Western blotting system (Amersham, Piscataway, NJ, USA). Expression of actin was also measured as an internal loading control using a specific antibody (Santa Cruz Biotechnology). The relative amounts of each protein were quantitated as ratios to actin indicated underneath each gel. Results represent three independent experiments.
Generation of stable transfectants
Stable transfectants were generated using the calcium-phosphate method as described previously . The TWIST expression vector was a gift from Dr C Glackin (Division of Moleculra Medicine, Beckman Research Institute of the City of Hope, CA, USA) (Lee et al., 1999) . After transfection of both TWIST expression vector (pcDNA3-TWIST) and the control vector (pcDNA3), the HNE1, TW04 and MGHU1 cells were selected in G418, and three pairs of stable transfectants were generated after 14 days drug selection. The selective concentration of G418 for each cell line was predetermined as the lowest concentration that led to 100% cell death. Untransfected controls were set up for each transfection to ensure efficient drug selection. The transfectants were routinely maintained in drug selection but removed when performing drug-sensitivity assays.
Results
Generation of acquired resistance to taxol in a human nasopharyngeal carcinoma cell line, HNE1
Nasopharyngeal carcinoma (NPC) cell line HNE1 was exposed to increased concentrations of taxol (starting with inhibition concentration of 50% (IC 50 ) ¼ 0.2 ng/ml) for over 12 months and the cell line HNE1-T3 was generated. A colony-forming assay showed that HNE1-T3 cells were 12.6 times more resistant to taxol than the parental line HNE1 when compared to their IC 50 values ( Figure 1a and Table 1 ). In addition, HNE1-T3 cells were also crossresistant to another microtubule inhibitor, vincristine (6.2-fold increase), compared to HNE1 cells. To examine if the acquired resistance to microtubule inhibitors in HNE1-T3 cells was mediated through multidrug-resistant phenotype, we next studied their cellular sensitivity to a further six commonly used anticancer drugs that are structurally and functionally unrelated. As shown in Figure 1b Role of TWIST in anticancer drug resistance X Wang et al resistance to taxol and vincristine in HNE1-T3 cells may be specific to microtubule-disrupting agents.
Identification and characterization of TWIST gene amplification in HNE1-T3 cells
To investigate mechanisms involved in taxol-induced resistance in HNE1-T3 cells, we analysed genomic profiles of HNE1 and HNE1-T3 cell lines and compared the alterations at the chromosomal level using comparative genome hybridization (CGH). As shown in Figure 2 , the HNE1-T3 cell line showed almost identical chromosomal profiles to HNE1 cells, indicating that these cells were derived from the HNE1 cell line. Three chromosomal regions showed differences between the two cell lines; chromosome 7p21-22 region, which was amplified in HNE1-T3 cells (Figure 2 , see arrows), seemed to be related to cell survival as subsequent data base searches indicated that a candidate gene, named TWIST, was located in this region (El Ghouzzi et al., 1997) . Although no report has demonstrated the role of TWIST in chemodrug resistance, recently it has been indicated as an antiapoptotic factor (Maestro et al., 1999) . To further investigate the possibility that TWIST expression was upregulated in HNE1-T3 cells, RT-PCR and Western blotting analysis were performed. As shown in Figure 3a , TWIST mRNA and protein expressions were 4.0-and 5.2-fold higher in HNE1-T3 cells as compared to HNE1 cells, respectively, which confirms the CGH results and indicates a TWIST gene amplification in HNE1-T3 cells. Since p53, p21 Waf1 , MDM2, Bax proteins have been reported to be downstream factors of the TWIST protein (Maestro et al., 1999; Funato et al., 2001; Yousfi et al., 2002) , we next studied the expression of these proteins in HNE1-T3 and HNE1 cells. As shown in Figure 3b , p53, p21
Waf1 protein levels were low in HNE1-T3 cells, but MDM2 levels were high, which agrees with a previous study that TWIST may negatively interfere with the p53 tumour suppressor pathway (Maestro et al., 1999) . In addition, we also observed an approximate 90% reduction in Bax levels in HNE1-T3 cells, while there was a slight decrease in Bcl-2 expression (Figure 3c ). These results support previous evidence that TWIST expression was associated with decreased Bax but not Bcl-2 levels in osteoblast cells from patients suffering from Saethre-Chotzen syndrome, which is one of the most common autosomal dominant disorders of craniosynostosis (early closing of one or more of the sutures of an infant's head), and TWIST inactivation is thought to be one of the mechanisms responsible (El Ghouzzi et al., 1997; Howard et al., 1997; Yousfi et al., 2002) .
Since resistance to microtubule-disrupting agents can develop through expression of efflux pumps such as Pglycoprotein (or multidrug resistance, MDR-1) (Germann, 1996; Dumontet and Sikic, 1999) , we next examined the expression of the MDR-1 protein in HNE1 and HNE1-T3 cells. As shown in Figure 4 , we did not observe any significant increase in MDR-1 protein levels in HNE1-T3 cells. As taxol resistance can also develop with alterations either in the primary structure or in the level of tubulin isotype (Giannakakou et al., 1997; Kavallaris et al., 1997; Ranganathan et al., 1998) , we also studied the expression of total tubulin protein levels in both cell lines. As with observed MDR- 
(a) RT-PCR analysis of TWIST mRNA expression (top gel) and Western blotting analysis of TWIST protein expression (bottom gel). (b) and (c) Western blotting analysis of p53, p21
Waf1 , MDM2, Bcl-2 and Bax expression. The level of actin was detected as an internal loading control. The relative amounts of each protein were quantitated as ratios to actin indicated underneath each gel. Results represent three independent experiments. Note that increased TWIST expression is associated with decreased p53, p21
Waf1 and Bax expression in HNE1-T3 cells Figure 4 Western blotting analysis of MDR-1, tubulin, MAD2 and p55CDC in HNE1 and HNE1-T3 cells. The relative amounts of each protein were quantitated as ratios to actin indicated underneath each gel. Results represent three independent experiments. Note that increased MDR-1 and tubulin and decreased MAD2 and p55CDC are shown in HNE1-T3 cells
Role of TWIST in anticancer drug resistance X Wang et al 1 levels, there was only an approximately 50% increase in tubulin protein expression in HNE1-T3 cells. Alterations in the expression of key mitotic checkpoint proteins such as MAD2 and p55CDC have also been suggested to effect cellular sensitivity to mitotic-targeting agents (Wang et al., 2003) ; in this study, HNE1-T3 cells had a slight decrease (approximately 20-30%) in MAD2 and p55CDC levels compared to HNE1 cells. These results indicate that in addition to TWIST amplification, moderate alterations in MDR-1, tubulin, MAD2 and p55CDC expression levels may also contribute to the acquired resistance to taxol and vincristine in HNE1-T3 cells.
Association of TWIST expression and taxol resistance in human nasopharyngeal, bladder, ovarian and prostate cancer cell lines
To further investigate whether TWIST expression was also associated with resistance to taxol and vincristine in additional cancer types, we studied eight cell lines (four pairs) derived from human nasopharyngeal (CNE2, TW04), bladder (RT112, MGHU1), ovarian (Ovca433, Ovca432) and prostatic (PC3, LNCaP) carcinomas with differential TWIST expression levels. As shown in Figure 5 , all the cell lines with relatively high TWIST expression (CNE2, RT112, Ovca433 and PC3) were more resistant to taxol and vincristine compared to the cell lines derived from same cell type with relatively low levels of TWIST (TW04, MGHU1, Ovca432 and LNCaP). Comparing their IC 50 values, the cell lines with high levels of TWIST were 1.5-2.5-fold more resistant to taxol and 1.8-6.5-fold more resistant to vincristine than the lines with relatively low levels of TWIST (Table 2 ). It is possible that different cell lines contain distinct genetic backgrounds that may influence the cellular sensitivity to taxol and vincristine; therefore, the TWIST expression levels were not closely correlated to increased resistance to these two drugs among those cell lines. However, these results suggest that upregulation of TWIST expression is associated with cellular resistance all four cancer types, indicating that it may be a general phenomenon in human cancers, rather than a specific event in HNE1-T3 cells.
Ectopic TWIST expression leads to resistance to taxol and vincristine in human cancer cells
To further confirm the role of TWIST in cellular resistance to taxol and vincristine, we transfected a TWIST expression vector (pcDNA3-TWIST) (Lee et al., 1999) and the control vector (pcDNA3) into the original parental HNE1 cell line, an additional NPC cell line TW04 and a bladder cancer cell line MGHU1. Three pairs of stable transfectants were generated by selecting in G418 (300 mg/ml). Western blotting analysis was then performed to examine TWIST expression in each transfectant compared to the vector control. As shown in Figure 6 , there was increased TWIST expression (2.5-3.5-fold) in all of the cell lines transfected with TWIST expression vector compared to the controls transfected with an empty control vector (pcDNA3). Subsequent cell growth studies showed that both TWIST-transfected and the vector control cell lines had similar growth rate (data not shown), indicating that introduction of TWIST did not alter cell proliferation rate in these cell lines. Colony-forming assays showed that HNE1-TWIST cells were 8.5-fold more resistant to taxol than the vector control HNE1-pcDNA3 cells (IC 50HNE1-TWIST ¼ 1.7 ng/ ml; IC 50HNE1-pcDNA3 ¼ 0.2 ng/ml) (Figure 6a ). In Figure 5 Association of TWIST expression and cellular sensitivity to taxol and vincristine in NPC (CNE2, TW04), bladder (RT112, MGHU1), ovarian (Ovca433, Ovca432) and prostate (PC-3, LNCaP) cancer cell lines. TWIST expression levels were determined by Western blotting analysis and the relative amounts of each protein were quantitated as ratios to actin indicated underneath each gel. Chemodrug sensitivity was determined by colonyforming assay as described in the legend of Figure 1 . The dotted lines represent cell lines with relatively high levels of TWIST expression, while the solid lines indicate cells with low TWIST expression. Note that increased TWIST expression is associated with resistance to taxol and vincristine Role of TWIST in anticancer drug resistance X Wang et al addition, HNE1-TWIST cells were also two-fold more resistant to vincristine than the vector control cells (IC 50HNE1-TWIST ¼ 1.76 ng/ml; IC 50HE1-pcDNA3 ¼ 0.86 ng/ml). These results confirm previous data demonstrating that increased TWIST expression plays a central role in the acquired taxol resistance of HNE1-T3 cell line (Figures 1-3 ) and strongly indicate that upregulation of TWIST plays a major part in both taxol and vincristine resistance in HNE1 cells. Ectopic TWIST expression also induced resistance to taxol and vincristine in an additional two cancer cell lines (Figure 6b and c) . As shown in Figure 6b , NPC cell line TW04-TWIST was two-fold more resistant to taxol (IC 50 ¼ 0.32 ng/ml) and 2.9-fold more resistant to vincristine (IC 50 ¼ 1.4 ng/ml) than the vector control HNE1-pcDNA3 cells (IC 50Taxol ¼ 0.16 ng/ml; IC 50vincris-tine ¼ 0.4 ng/ml). These results again indicate that the TWIST-induced resistance to these microtubuledisrupting agents may be a common phenotype in NPC cells, rather than a specific event in HNE1 cells. Colony-forming assays on the bladder cell lines MGHU1-TWIST and MGHU1-pcDNA3 (Figure 6c) showed that the TWIST transfectants were 3.1-and 9.8-fold more resistant to taxol (IC 50MGHU1-TWIST ¼ 1.5 ng/ml; IC 50MGHU1-pcDNA3 ¼ 0.4 ng/ml) and vincristine (IC 50MGHU1-TWIST ¼ 3.9 ng/ml; IC 50M-GHU1-pcDNA3 ¼ 0.4 ng/ml), respectively, than the vector control cells. These results further suggest that the TWIST-induced resistance may not be a specific event but a general phenomenon in human cancer.
Discussion
During generation of an acquired taxol-resistant cell line, we identified a novel role of the protein TWIST, in the development of taxol resistance in a nasopharyngeal carcinoma cell line (NPC), HNE1 (Figures 1-4) . Subsequent investigation on additional nasopharyngeal, bladder, ovarian and prostate cancer cell lines showed that upregulation of TWIST was associated with resistance to both taxol and vincristine ( Figure 5) , further implying that TWIST may be involved in the development of resistance to certain microtubule-disrupting agents in human cancer. The fact that ectopic expression of TWIST induced both taxol and vincristine resistance ( Figure 6 ) suggests its crucial role in the development of drug resistance. Our results indicate a Figure 6 Effect of ectopic TWIST expression on cellular sensitivity to taxol and vincristine in HNE1, TW04 and MGHU1 cells. Stable transfectants were generated using a TWIST expression vector and the control vector pcDNA3 (Lee et al., 1999) . TWIST expression was determined by Western blotting analysis and the relative amounts of each protein were quantitated as ratios to actin indicated underneath each gel. Colony-forming assay was then preformed to determine cellular sensitivity as described in the legend of Figure 1 . All experiments were derived from at least three independent experiments. Note that cells transfected with TWIST expression vector (dotted lines) show resistance to both taxol and vincristine compared to the vector control (solid lines)
Role of TWIST in anticancer drug resistance X Wang et al novel mechanism leading to acquired drug resistance in human cancer. TWIST was originally discovered as a Drosophila gene, whose mutation causes the characteristic 'TWISTED' phenotype in embryos (Thisse et al., 1988) . In human, TWIST germ line mutations and reduced TWIST protein levels are thought to be responsible for Saethre-Chotzen syndrome (El Ghouzzi et al., 1997; Howard et al., 1997) . The TWIST protein is a highly conserved transcription factor that belongs to the family of basic helix-loop-helix proteins (Olson and Klein, 1994) , which play a central role in cell type determination and differentiation (Olson and Klein, 1994) . It has been indicated that TWIST plays a crucial role in cranial osteogenesis, and TWIST haploinsufficiency enhances apoptosis in osteoblasts leading to premature fusion of calvarial bones (craniosynostosis) (Yousfi et al., 2002) . Although the function of TWIST is not fully established at the molecular level, recently TWIST has been indicated as a potential oncogene interfering with p53-related pathways leading to preventing myc-induced apoptosis in mouse embryonal fibroblasts (Maestro et al., 1999) . TWIST is also found to be involved in the suppression of differentiation and protection of apoptosis through inhibition of p21
Waf1 via both p53-dependent and -independent pathways (Funato et al., 2001; Hjiantoniou et al., 2003) . More recently, the antiapoptotic function of TWIST has been indicated through modulating NFkB pathways, and loss of TWIST expression leads to sensitization to TNFainduced apoptosis (Sosic et al., 2003) . In addition, downregulation of TWIST expression by antisense strategies increases sensitivity to etopside-induced cell death in mouse fibroblasts (Dupont et al., 2001) . These lines of evidence strongly indicate the positive role of TWIST in protection against cell death. In the present study, our findings that TWIST expression leads to cellular resistance to certain anticancer drugs further support its role as an antiapoptotic factor.
Although there is not sufficient evidence to indicate the role of TWIST in human tumorigenesis, especially carcinomas, a recent report showed that 50% of the rhabdomyosarcoma cases had high levels of TWIST, although only 15 cases were analysed (Maestro et al., 1999) . A recent study on 28 cases of gastric carcinomas showed that 39% of them (11 out of 28) had increased TWIST expression compared to the nonmalignant tissues (Rosivatz et al., 2002) . However, in a separate study, TWIST expression was not detected in human breast (n ¼ 6), gastric and colon (n ¼ 10), ovarian (n ¼ 4) and lung (n ¼ 10) carcinomas (Maestro et al., 1999) . It is possible that these discrepancies are due to either the relative small number of samples or different antibodies used in these studies. In the present study, we found TWIST expression in cell lines derived from four types of carcinomas originated from nasopharynx, bladder, ovary and prostate (Figure 5 ), supporting the hypothesis that in addition to osteogenesis, TWIST may also play a role in tumorigenesis. This is further supported by a recent study that activation of TWIST may contribute to tumorigenes, because it was identified as a common target for retro viral integration in MAV2 virus-induced chicken nephroblastoma (Pajer et al., 2003) . The results presented in this study have shown that TWIST is not only commonly expressed in human carcinomas, but may also play an important role in inducing acquired resistance to microtubule-disrupting anticancer drugs. These conclusions are supported by the following evidence: first, the taxol-resistant subline HNE1-T3 showed crossresistance to vincristine, which also targets microtubules with a slightly different mechanism, but not other anticancer drugs with different mechanisms of action (Figure 1 ). In addition, increased TWIST expression was also associated with taxol and vincristine resistance in all four cancer types ( Figure 5 ). Second, transfection of TWIST gene into the original parental line HNE1 led to resistance to both taxol and vincristine, although the degree of resistance was lower than that in HNE1-T3 cells (12.6-and 6.2-fold versus 8.5-and two-fold, respectively, Figures 1 and 6 ). It is possible that additional minor alterations that occurred during selection process in HNE1-T3 cells may contribute to the high degree of resistance (Figure 4 ). In addition, transfection of TWIST into additional cancer cell lines also increased resistance to both taxol and vincristine ( Figure 6 ). Therefore, our findings indicate a novel mechanism in which upregulation of TWIST plays a central role in the development of resistance to microtubule-disrupting anticancer drugs.
As discussed, TWIST functions as an antiapoptotic factor. It is possible that the TWIST-induced drug resistance results from interference with p53-related pathways. As shown in Figure 3 , decreased p53, p21 Waf1 but not MDM2 was found in the subline HNE1-T3 cells compared to the parental line HNE1, while downregulation of Bax, an factor, was observed pre-apoptotic in HNE1-T3 cells. These results also agree with previous reports that TWIST suppresses expression of p53, p21
Waf1 and Bax leading to decreased apoptosis in osteoblast cells (Maestro et al., 1999; Yousfi et al., 2002) . We are currently investigating the effect of exogenous TWIST expression on p53, p21
Waf1 , Bax and Bcl-2 expression in the stable transfectants generated in the present study to further confirm this hypothesis. Since a number of studies have indicated the involvement of MAPK and NFkB pathways in the development of taxol resistance (McDaid and Horwitz, 2001; Huang et al., 2000) and recent linkage of TWIST with these two pathways (Dupont et al., 2001; Sosic et al., 2003) , we are also currently studying the role of MAPK and NFkB pathways in TWIST-induced drug resistance in human cancer.
In summary, in this study, we identified a novel role of TWIST protein in the development of resistance to microtubule-disrupting anticancer drugs in human cancer. Since taxol and vincristine are frequently used in the treatment of many types of human cancer, our results indicate a novel therapeutic strategy to overcome acquired resistance through inactivation of TWIST expression in human cancer.
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